Showing results (2491-2500 of 3,717) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|March 29, 2017
MPT0B002, a novel microtubule inhibitor, downregulates T315I mutant Bcr-Abl and induces apoptosis of imatinib-resistant chronic myeloid leukemia cellsYi-Yen Yeh, Jing-Ping Liou, Yueh-Lun Lee, et al.
Investigational New Drugs|November 20, 2012
A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumorsJohn Marshall, Jimmy Hwang, Ferry A L M Eskens, et al.
Investigational New Drugs|November 20, 2012
Clinical trial design in biosimilar drug developmentG Dranitsaris, K Dorward, E Hatzimichael, et al.
Investigational New Drugs|April 12, 2012
Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m(2) every 21 days in patients with cancerGlen J Weiss, Ross C Donehower, Tara Iyengar, et al.
Investigational New Drugs|September 13, 2014
Randomized phase III trial of regorafenib in metastatic colorectal cancer: analysis of the CORRECT Japanese and non-Japanese subpopulationsTakayuki Yoshino, Yoshito Komatsu, Yasuhide Yamada, et al.
Investigational New Drugs|October 23, 2014
A phase Ib study of linsitinib (OSI-906), a dual inhibitor of IGF-1R and IR tyrosine kinase, in combination with everolimus as treatment for patients with refractory metastatic colorectal cancerJohanna C Bendell, Suzanne F Jones, Lowell Hart, et al.
Investigational New Drugs|August 10, 2014
Ellipticine derivative induces potent cytostatic effect in acute myeloid leukaemia cellsE G Russell, E C O'Sullivan, C M Miller, et al.
Investigational New Drugs|August 3, 2014
CG100649, a novel COX-2 inhibitor, inhibits colorectal adenoma and carcinoma growth in mouse modelsSun-Hee Kim, Ofer Margalit, Hiroshi Katoh, et al.
Investigational New Drugs|November 21, 2013
SHetA2 interference with mortalin binding to p66shc and p53 identified using drug-conjugated magnetic microspheresDoris Mangiaracina Benbrook, Baskar Nammalwar, Andrew Long, et al.
Investigational New Drugs|July 20, 2014
A phase I, dose-escalation trial of continuous- and pulsed-dose afatinib combined with pemetrexed in patients with advanced solid tumorsQuincy S Chu, Randeep Sangha, Sebastien J Hotte, et al.
Pageof 372